» Articles » PMID: 26810647

Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus Fumigatus, and the Frequency of Resistance at One Center

Overview
Specialty Pharmacology
Date 2016 Jan 27
PMID 26810647
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Studies of cystic fibrosis (CF) patient exacerbations attributed toPseudomonas aeruginosainfection have indicated a lack of correlation of outcome within vitrosusceptibility results. One explanation is that the media used for testing do not mimic the airway milieu, resulting in incorrect conclusions. Therefore, media have been devised to mimic CF sputum.Aspergillus fumigatusis the leading fungal pathogen in CF, and susceptibility testing is also used to decide therapeutic choices. We assessed whether media designed to mimic CF sputa would give different fungal susceptibility results than those of classical methods, assaying voriconazole, the most utilized anti-Aspergillusdrug in this setting, and 30 CFAspergillusisolates. The frequency of marked resistance (defined as an MIC of >4 μg/ml) in our CF unit by classical methods is 7%. Studies performed with classical methods and with digested sputum medium, synthetic sputum medium, and artificial sputum medium revealed prominent differences inAspergillussusceptibility results, as well as growth rate, with each medium. Clinical correlative studies are required to determine which results are most useful in predicting outcome. Comparison of MICs with non-CF isolates also indicated the CF isolates were generally more resistant.

Citing Articles

Anti-Fungal () Activity of in Cystic Fibrosis Synthetic Sputum.

Sass G, Kethineni S, Stevens D Pathogens. 2024; 13(10).

PMID: 39452746 PMC: 11510391. DOI: 10.3390/pathogens13100875.


Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule.

Larwood D, Stevens D Antibiotics (Basel). 2024; 13(5).

PMID: 38786134 PMC: 11117233. DOI: 10.3390/antibiotics13050405.


Consumption of Airway Metabolites Promotes Lung Infection.

Riquelme S, Prince A Pathogens. 2021; 10(8).

PMID: 34451421 PMC: 8401524. DOI: 10.3390/pathogens10080957.


Azole-Resistance Development; How the Lifecycle Defines the Potential for Adaptation.

Zhang J, Debets A, Verweij P, Snelders E J Fungi (Basel). 2021; 7(8).

PMID: 34436138 PMC: 8397044. DOI: 10.3390/jof7080599.


Impact of Artificial Sputum Medium Formulation on Pseudomonas aeruginosa Secondary Metabolite Production.

Neve R, Carrillo B, Phelan V J Bacteriol. 2021; 203(21):e0025021.

PMID: 34398662 PMC: 8508215. DOI: 10.1128/JB.00250-21.


References
1.
Shoseyov D, Brownlee K, Conway S, Kerem E . Aspergillus bronchitis in cystic fibrosis. Chest. 2006; 130(1):222-6. DOI: 10.1378/chest.130.1.222. View

2.
Xiao W, Hsu Y, Ishizaka A, Kirikae T, Moss R . Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest. 2005; 128(4):2316-26. DOI: 10.1378/chest.128.4.2316. View

3.
Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60. DOI: 10.1086/525258. View

4.
Vanhee L, Symoens F, Bouchara J, Nelis H, Coenye T . High-resolution genotyping of Aspergillus fumigatus isolates recovered from chronically colonised patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2008; 27(10):1005-7. DOI: 10.1007/s10096-008-0527-1. View

5.
de Valk H, Klaassen C, Yntema J, Hebestreit A, Seidler M, Haase G . Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. J Cyst Fibros. 2008; 8(2):110-4. DOI: 10.1016/j.jcf.2008.10.003. View